Literature DB >> 27531701

Pancreatic cancer: Clinical practice guidelines - what is the evidence?

Oliver Strobel1, Markus W Büchler1.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27531701     DOI: 10.1038/nrclinonc.2016.127

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

Review 1.  Meta-analysis of radical resection rates and margin assessment in pancreatic cancer.

Authors:  M D Chandrasegaram; D Goldstein; J Simes; V Gebski; J G Kench; A J Gill; J S Samra; N D Merrett; A J Richardson; A P Barbour
Journal:  Br J Surg       Date:  2015-09-09       Impact factor: 6.939

2.  Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients.

Authors:  Thilo Hackert; Milena Sachsenmaier; Ulf Hinz; Lutz Schneider; Christoph W Michalski; Christoph Springfeld; Oliver Strobel; Dirk Jäger; Alexis Ulrich; Markus W Büchler
Journal:  Ann Surg       Date:  2016-09       Impact factor: 12.969

3.  Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma.

Authors:  Peter J Allen; Deborah Kuk; Carlos Fernandez-Del Castillo; Olca Basturk; Christopher L Wolfgang; John L Cameron; Keith D Lillemoe; Cristina R Ferrone; Vicente Morales-Oyarvide; Jin He; Matthew J Weiss; Ralph H Hruban; Mithat Gönen; David S Klimstra; Mari Mino-Kenudson
Journal:  Ann Surg       Date:  2017-01       Impact factor: 12.969

Review 4.  FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.

Authors:  Mustafa Suker; Berend R Beumer; Eran Sadot; Lysiane Marthey; Jason E Faris; Eric A Mellon; Bassel F El-Rayes; Andrea Wang-Gillam; Jill Lacy; Peter J Hosein; Sing Yu Moorcraft; Thierry Conroy; Florian Hohla; Peter Allen; Julien Taieb; Theodore S Hong; Ravi Shridhar; Ian Chau; Casper H van Eijck; Bas Groot Koerkamp
Journal:  Lancet Oncol       Date:  2016-05-06       Impact factor: 41.316

5.  Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Edward P Balaban; Pamela B Mangu; Alok A Khorana; Manish A Shah; Somnath Mukherjee; Christopher H Crane; Milind M Javle; Jennifer R Eads; Peter Allen; Andrew H Ko; Anitra Engebretson; Joseph M Herman; John H Strickler; Al B Benson; Susan Urba; Nelson S Yee
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

6.  Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alok A Khorana; Pamela B Mangu; Jordan Berlin; Anitra Engebretson; Theodore S Hong; Anirban Maitra; Supriya G Mohile; Matthew Mumber; Richard Schulick; Marc Shapiro; Susan Urba; Herbert J Zeh; Matthew H G Katz
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

Review 7.  Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Davendra P S Sohal; Pamela B Mangu; Alok A Khorana; Manish A Shah; Philip A Philip; Eileen M O'Reilly; Hope E Uronis; Ramesh K Ramanathan; Christopher H Crane; Anitra Engebretson; Joseph T Ruggiero; Mehmet S Copur; Michelle Lau; Susan Urba; Daniel Laheru
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

8.  Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

Authors:  John P Neoptolemos; Deborah D Stocken; Claudio Bassi; Paula Ghaneh; David Cunningham; David Goldstein; Robert Padbury; Malcolm J Moore; Steven Gallinger; Christophe Mariette; Moritz N Wente; Jakob R Izbicki; Helmut Friess; Markus M Lerch; Christos Dervenis; Attila Oláh; Giovanni Butturini; Ryuichiro Doi; Pehr A Lind; David Smith; Juan W Valle; Daniel H Palmer; John A Buckels; Joyce Thompson; Colin J McKay; Charlotte L Rawcliffe; Markus W Büchler
Journal:  JAMA       Date:  2010-09-08       Impact factor: 56.272

9.  Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories.

Authors:  Oliver Strobel; Ulf Hinz; Alexander Gluth; Thomas Hank; Thilo Hackert; Frank Bergmann; Jens Werner; Markus W Büchler
Journal:  Ann Surg       Date:  2015-05       Impact factor: 12.969

10.  Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS).

Authors:  Maximilian Bockhorn; Faik G Uzunoglu; Mustapha Adham; Clem Imrie; Miroslav Milicevic; Aken A Sandberg; Horacio J Asbun; Claudio Bassi; Markus Büchler; Richard M Charnley; Kevin Conlon; Laureano Fernandez Cruz; Christos Dervenis; Abe Fingerhutt; Helmut Friess; Dirk J Gouma; Werner Hartwig; Keith D Lillemoe; Marco Montorsi; John P Neoptolemos; Shailesh V Shrikhande; Kyoichi Takaori; William Traverso; Yogesh K Vashist; Charles Vollmer; Charles J Yeo; Jakob R Izbicki
Journal:  Surgery       Date:  2014-02-07       Impact factor: 3.982

  10 in total
  5 in total

1.  Circular RNA circ-LDLRAD3 as a biomarker in diagnosis of pancreatic cancer.

Authors:  Fan Yang; Dong-Yan Liu; Jin-Tao Guo; Nan Ge; Ping Zhu; Xiang Liu; Sheng Wang; Guo-Xin Wang; Si-Yu Sun
Journal:  World J Gastroenterol       Date:  2017-12-21       Impact factor: 5.742

2.  Role of surgery in pancreatic cancer.

Authors:  Trond A Buanes
Journal:  World J Gastroenterol       Date:  2017-06-07       Impact factor: 5.742

3.  Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer?

Authors:  Mingxing Wang; Pengfei Zhu; Zheling Chen; Liu Yang
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248

Review 4.  Optimizing the outcomes of pancreatic cancer surgery.

Authors:  Oliver Strobel; John Neoptolemos; Dirk Jäger; Markus W Büchler
Journal:  Nat Rev Clin Oncol       Date:  2019-01       Impact factor: 66.675

Review 5.  Conversion Surgery for Advanced Pancreatic Cancer.

Authors:  Thomas Hank; Oliver Strobel
Journal:  J Clin Med       Date:  2019-11-12       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.